WikiDoc state of the art review on bivalirudin

Jump to navigation Jump to search

WikiDoc Resources for WikiDoc state of the art review on bivalirudin

Articles

Most recent articles on WikiDoc state of the art review on bivalirudin

Most cited articles on WikiDoc state of the art review on bivalirudin

Review articles on WikiDoc state of the art review on bivalirudin

Articles on WikiDoc state of the art review on bivalirudin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on WikiDoc state of the art review on bivalirudin

Images of WikiDoc state of the art review on bivalirudin

Photos of WikiDoc state of the art review on bivalirudin

Podcasts & MP3s on WikiDoc state of the art review on bivalirudin

Videos on WikiDoc state of the art review on bivalirudin

Evidence Based Medicine

Cochrane Collaboration on WikiDoc state of the art review on bivalirudin

Bandolier on WikiDoc state of the art review on bivalirudin

TRIP on WikiDoc state of the art review on bivalirudin

Clinical Trials

Ongoing Trials on WikiDoc state of the art review on bivalirudin at Clinical Trials.gov

Trial results on WikiDoc state of the art review on bivalirudin

Clinical Trials on WikiDoc state of the art review on bivalirudin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on WikiDoc state of the art review on bivalirudin

NICE Guidance on WikiDoc state of the art review on bivalirudin

NHS PRODIGY Guidance

FDA on WikiDoc state of the art review on bivalirudin

CDC on WikiDoc state of the art review on bivalirudin

Books

Books on WikiDoc state of the art review on bivalirudin

News

WikiDoc state of the art review on bivalirudin in the news

Be alerted to news on WikiDoc state of the art review on bivalirudin

News trends on WikiDoc state of the art review on bivalirudin

Commentary

Blogs on WikiDoc state of the art review on bivalirudin

Definitions

Definitions of WikiDoc state of the art review on bivalirudin

Patient Resources / Community

Patient resources on WikiDoc state of the art review on bivalirudin

Discussion groups on WikiDoc state of the art review on bivalirudin

Patient Handouts on WikiDoc state of the art review on bivalirudin

Directions to Hospitals Treating WikiDoc state of the art review on bivalirudin

Risk calculators and risk factors for WikiDoc state of the art review on bivalirudin

Healthcare Provider Resources

Symptoms of WikiDoc state of the art review on bivalirudin

Causes & Risk Factors for WikiDoc state of the art review on bivalirudin

Diagnostic studies for WikiDoc state of the art review on bivalirudin

Treatment of WikiDoc state of the art review on bivalirudin

Continuing Medical Education (CME)

CME Programs on WikiDoc state of the art review on bivalirudin

International

WikiDoc state of the art review on bivalirudin en Espanol

WikiDoc state of the art review on bivalirudin en Francais

Business

WikiDoc state of the art review on bivalirudin in the Marketplace

Patents on WikiDoc state of the art review on bivalirudin

Experimental / Informatics

List of terms related to WikiDoc state of the art review on bivalirudin


Overview

Bivalirudin (Angiomax™) is a drug that belongs to the anticoagulant class and acts as a direct thrombin inhibitor.

Comparative Results

In a large comparative 30-days study encompassing 6,010 patients (called REPLACE2 study) Bivalirudin was compared with a standard therapy of either Abciximab or Eptifibatide plus initial Heparin bolus. The study had a randomized, double-blinded design. Regarding the primary endpoint (death, myocardial infarction, urgent revascularization procedures, severe bleedings) no statistically significant difference between Bivalirudin and standard therapy was noticed (9.2 versus 10.0 %). Regarding ischemic complications (death, myocardial infarction, and urgent revascularization procedures) there was also no statistically significant difference (7.6 vs. 7.1 %). But the risk for severe bleedings was 2.4 % in the Bivalirudin group compared to 4.1 % in the standard therapy-group; a significant difference. In an additional study comparing historical data of Heparin alone (EPISTENT, ESPRIT) with current Bivalirudin results, Bivalirudin gave superior results. Bivalirudin was licensed based on the results of both the REPLACE2 study and the historical data.

References


Template:WikiDoc Sources